onr:"swepub:oai:gup.ub.gu.se/107164"
Search: onr:"swepub:oai:gup.ub.gu.se/107164" > Histamine dihydroch...
- 1 of 1
- Previous record
- Next record
- To hitlist
Histamine dihydrochloride and low-dose interleukin-2 as post-consolidation immunotherapy in acute myeloid leukemia.
-
- Bergh Thorén, Fredrik, 1976 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för biomedicin, avdelningen för infektionssjukdomar,Institutionen för medicin, avdelningen för invärtesmedicin,Institute of Biomedicine, Department of Infectious Medicine,Institute of Medicine, Department of Internal Medicine
-
- Romero, Ana, 1975 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för biomedicin, avdelningen för infektionssjukdomar,Institute of Biomedicine, Department of Infectious Medicine
-
- Brune, Mats, 1950 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för invärtesmedicin,Institute of Medicine, Department of Internal Medicine
- show more...
- show less...
- (creator_code:org_t)
- 2009-08-05
- 2009
- English.
- In: Expert opinion on biological therapy. - : Informa Healthcare. - 1744-7682 .- 1471-2598. ; 9:9, s. 1217-23
- Research review (peer-reviewed)
Abstract
Subject headings
Close
- Acute myeloid leukemia (AML) is the most common acute leukemia in adults. Although most patients achieve complete remission (CR) after chemotherapy, the majority suffer from subsequent leukemic relapse, which is associated with poor long-term survival. Thus, new therapies to maintain CR are highly warranted. After the completion of chemotherapy, AML patients have a minimal burden of leukemic cells, which are reportedly susceptible to cytotoxic lymphocytes such as NK cells and T cells. A therapy that boosts the function of these effector cells therefore has the potential to eradicate the malignant clone in AML and prevent relapse, Here, we briefly review the literature on the role of the immune system in AML and introduce the rationale for the use of histamine dihydrochloride (HDC) in conjuction with low-dose IL-2 as relapse-preventive immunotherapy for this disease.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Immunologi inom det medicinska området (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Immunology in the medical area (hsv//eng)
Keyword
- Dose-Response Relationship
- Drug
- Histamine
- administration & dosage
- adverse effects
- therapeutic use
- Humans
- Immunotherapy
- Interleukin-2
- administration & dosage
- adverse effects
- therapeutic use
- Killer Cells
- Natural
- immunology
- Leukemia
- Myeloid
- Acute
- drug therapy
- immunology
- T-Lymphocytes
- immunology
Publication and Content Type
- ref (subject category)
- for (subject category)
Find in a library
- Expert opinion on biological therapy (Search for host publication in LIBRIS)
To the university's database
- 1 of 1
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Bergh Thorén, Fr ...
- Romero, Ana, 197 ...
- Brune, Mats, 195 ...
- Hellstrand, Kris ...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Basic Medicine
- and Immunology in th ...
- Articles in the publication
- Expert opinion o ...
- By the university
- University of Gothenburg
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
